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Caspase-8 is frequently deleted or silenced in neuroblastoma and other solid tumor such as medulloblastoma and small cell lung carcinoma.
Caspase-8 expression can be re-established in neuroblastoma cell lines by treatment with demethylating agents or with IFN-γ. Here we show that
four different retinoic acid (RA) derivatives also increase caspase-8 protein expression in neuroblastoma, medulloblastoma and small cell lung
carcinoma cell lines. This increase in protein expression is mirrored by an increase in RNA expression in NB cells. However, the promoter region
of the caspase-8 gene was not responsible for the induction of caspase-8 expression. Rather, we identified another intronic region containing a
CREB binding site that was required for maximal induction of caspase-8 via RA. DNA–protein interaction assays revealed increased phospho-
CREB binding to this response element in RA-treated NB cells. Furthermore, mutations of the CREB binding site completely blocked caspase-8
induction in the luciferase reporter system assay and transfection of dominant-negative form of CREB repressed the up-regulation of caspase-8 by
RA. Importantly, RA-released cells maintained caspase-8 expression for at least 2–5 days and were more sensitive to doxorubicin and TNFα.
Thus, RA treatment in conjunction with TNFα and/or subsets of cytotoxic agents may have therapeutic benefits.
© 2008 Elsevier B.V. All rights reserved.Keywords: Caspase-8; Neuroblastoma; Medulloblastoma; Small cell lung carcinoma; Retinoid; Retinoic acid; CREB; Apoptosis; Transcription1. Introduction
Neuroblastoma (NB) is the most common solid tumor in
childhood, accounting for approximately 10% of pediatric
cancers [1–3]. Several genetic abnormalities have been identified
in these tumors, including N-myc amplification, chromosomal
deletion and rearrangement of 1p36, 2q33, 11q23, and14q23, and
unbalanced gain of 17q23 [2–4]. Caspase-8 is also deleted or
silenced in the majority of NB cell lines and patients [5–7].
Studies using animal model systems and NB cell lines have
shown that the loss of caspases-8 potentiates metastasis [8–10].
Caspase-8 has an important role in the death receptor mediated
apoptotic pathway. The death receptor (or extrinsic) pathway is
triggered by members of the death receptor superfamily (FasR,
TNFRI, DR5, etc). Binding of the ligand (e.g., FasL) to its receptor
(FasR) induces aggregation of the receptors, leading to the⁎ Corresponding author. Tel.: +1 901 495 3501; fax: +1 901 495 2381.
E-mail address: jill.lahti@stjude.org (J.M. Lahti).
0167-4889/$ - see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2008.02.007recruitment of an adaptor molecule known as FADD (Fas receptor
associated death domain containing protein) and procaspase-8.
Procaspase-8 is then cleaved and activated, resulting in the acti-
vation of downstream effector caspases and leading to apoptosis.
Active caspase-8 can also cleave Bid, which is a Bcl2 family
member. Cleaved Bid, termed tBid, translocates to the mitochon-
dria and promotes cytochrome c release, thereby activating the
mitochondrial (or intrinsic) pathway [11–13]. Caspase-8 expres-
sion is also lost in other solid tumors including medulloblastoma
[14], small cell lung carcinoma [15] and colorectal carcinomas [16].
Loss of caspase-8 expression inmedulloblastoma patients has been
correlated with a poor prognosis [17].
All-trans retinoic acid (ATRA or RA), which is a derivative of
vitamin A, is effective in inducing differentiation and inhibiting
proliferation of NB cell lines [18–20]. The differentiation of NB
cells induced by RA is accompanied by changes in gene
expression, including N-myc down-regulation [21,22]. RA is
well tolerated in clinical trials, improves survival in NB patients
and even induces occasional long-term remission [21,23,24]. RA
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retinoic acid receptors (RARs), which form heterodimers with
retinoidX receptors (RXRs). RAR-RXRheterodimers bind toRA
response elements (RAREs) to regulate gene transcription. The
RAREs are generally composed of two direct repeats (DR) with
the consensus sequence AG(G/T)TCA spaced by 2 or 5 nucleo-
tides (DR2 or DR5) [25,26]. Although the majority of RAREs are
located in the promoter region of RA-responsive genes, they are
also found in introns or exons or downstream of the RA-
responsive genes [26,27]. However, recent studies showed that
RA could stimulate other cellular signaling pathways, which areFig. 1. RA increased caspase-8 expression. (A) Induction of caspase-8 by RA is tim
(10 μM or 25 μM) for 10 days or treated with 100 μM RA for 3 days. Aliquots w
antibodies against caspase-8 and actin. (B) Time course analysis of caspase-8 levels
continuously with RA for 1 to 4 days or treated with RA for 2 days and released into f
to immunoblot analysis. (C) Induction of caspase-8 mRNA measured by real-time P
mRNA content was analyzed by real-time PCR. The caspase-8 mRNA expression wa
untreated control samples was set as 1 for each cell lines. The values represent the me
retinoids in NB cells. NB8, NB10 and NB16 cells were treated with either RA (AT
subjected to immunoblot analysis. (E) Induction of caspase-8 by retinoids in medullob
and small cell lung carcinoma (NCI-H82, NCI-H889) cell lines were treated with thindependent on the binding of receptors to RAREs [28–30]. For
examples, RA can regulate PKCα activity by competing with
phosphatidylserine to bind to the C2-domain of PKCα [29,30].
RA can also up-regulate the c-fos gene although it does not
contain RAREs in its promoter [28]. The present study analyzed
the effects of RA treatment on caspase-8 expression and cellular
proliferation in NB cells. The results demonstrate that RA induces
caspase-8 mRNA and protein expression in NB cell lines via
induction of phosphorylated CREB and the binding of this
transcription factor to sequences within the caspase-8 gene,
thereby sensitizing the cells to TNFα- or drug-induced apoptosis.e and dose dependent. NB8 and NB10 cells were treated continuously with RA
ere collected at the indicated times and subjected to immunoblot analysis with
in NB cells treated with 100 μM RA. NB8, NB10 and NB16 cells were treated
resh medium. The cells were collected at the indicated times, lysed and subjected
CR. NB8, NB10 and NB16 cells were treated with RA for 48 h and caspase-8
s normalized to GADPH and the value for the relative amount of caspase-8 in the
ans±SD from at least 3 independent experiments. (D) Induction of caspase-8 by
RA), 9-cis RA, 13-cis RA (100 μM) or 4HPR (10 μM) for 3 days, lysed and
lastoma and small cell lung carcinoma cell lines. Medulloblastoma (BT-3, BT-4)
e indicated retinoids for 3 days, prior to lysis and immunoblot analysis.
Table 1
Analysis of CASP8 during and after RA treatment in human NB cell lines
Cell
line
Control RA treatment RA release
Casp8
expressiona
CASP8
methylationb
Casp8
protein up-
regulationc
Methylation
status
changed
Maintenance
of Casp8 up-
regulation
(days)
NB4 − Y 1 ND 10
NB6 − Y 3 ND 5
NB8 − Y 3 N 15
NB10 − Y 3 Y N120
NB12 − Y 1 N 2
NB13 − Y 1 ND 2
NB14 − Y 2 ND 5
NB15 + N 1 N 2
NB16 + N 1 N 2
NB17 − Y 0 ND N
NB19 − Y 1 N 2
SKNDZ − ND 1 ND 2
a,bFrom Teitz et al. [5] and references therein; ND, not determined.
cThe relative level of caspase-8 expression during RA treatment on a scale of 0
(minimal increase) to 3 (highest).
dThe change of methylation status as determined by MS-PCR; N, no change;
Y, changed (from methylation to demethylation); ND, not determined.
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2.1. Cell lines and culture methods
The human NB cell lines used in these studies have been described in detail
previously [5,31]. All the human neuroblastoma, medulloblastoma (BT-3, BT-14)
and small cell lung carcinoma (NCI-H82, NCI-H889) cell lines were cultured in
RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, and 0.1%
gentamicin (Invitrogen, CA, USA) in a humidified atmosphere of 5% CO2 at
37 °C.
2.2. Reagents and antibodies
All-trans RA (ATRA or RA), 13-cis RA, 9-cis RA, fenretinide (4HPR),
doxorubicin, cycloheximide and MTTwere purchased from Sigma (MO, USA).
zVAD-fmk and z-IETD-fmk were purchased from Calbiochem (Germany).
TNFα was purchased from Promega (WI, USA).
Anti-caspase-8 (C15) was a gift from Dr. M. Peter [32]. Anti-CREB, anti-
phospho-CREB (Ser-133) and anti-PARPwere obtained fromUpstate Biotechnol-
ogy (MA, USA). Actin, Fas and FADD antibodies were obtained from Santa Cruz
Biotechnology (CA, USA). Caspase-3, DR4 and DR5 antibodies were purchased
fromBDBiosciences (CA,USA).Anti-TNFR1was purchased fromCell Signaling
Technology (MA, USA) and anti-GFP was obtained from Invitrogen (CA, USA).
Horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained
from KPL (MD, USA).
2.3. Western blot
Cells were lysed with the loading buffer (50 mM Tris, pH 6.8, 100 mMDTT,
2% SDS, 10% glycerol and 0.1% bromophenol blue). Thirty micrograms of
protein from the cell lysates was subjected to SDS-PAGE analysis. Immunoblot
analysis was carried out with unlabeled primary antibodies and HRP-conjugated
secondary antibodies. The proteins were detected by enhanced chemilumines-
cence (ECL, GE Healthcare, NJ, USA).
2.4. Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) were carried out as described
previously [33] with some modifications. Briefly, nuclear extracts (5 μg) prepared
from RA-treated or untreated NB cells were incubated with 1 μl 32P-end-labeled
double-stranded oligonucleotides (10000 cpm/μl) and 2 μg poly(dI-dC) in 20 μl
binding buffer (10 mMHEPES, pH 8.0, 50 mMNaCl, 5 mMMgCl2, 2 mMDTT,
10% Glycerol) for 20 min at room temperature. Two micrograms of anti-phospho-
CREB (Ser133) antibodywas added to the nuclear extract and incubated for 20min
for the supershift analysis. The DNA–protein complexes were resolved in a 4%
native polyacrylamide gel. Following electrophoresis, the gels were dried and
autoradiographed at−80 °C for 3–16 h. The oligonucleotides used in this study are
listed in the figure legends.
2.5. Methylation-specific PCR and real-time PCR
GenomicDNA isolated fromNB cells was bisulfite-modifiedwith an EZDNA
Methylation kit (Zymo Research, CA, USA) according to the manufacturer's
instructions. The modified genomic DNAwas then used for methylation-specific
PCR (MSP) studies using the caspase-8 methylation primer sets previously
described [5].
Total RNAwas extracted from NB cells with TRIzol reagent (Invitrogen, CA,
USA) and residual DNAwas removed by theRNeasyMini kit (Qiagen, CA,USA).
Purified RNAs (2 μg) were then used to synthesize cDNA using Superscript II
(Invitrogen, CA, USA) and random primers (Promega,WI, USA). The primers for
the analysis for caspase-8 mRNA expression were 5′-TGTTGGAGGAAAG-
CAATCTG-3′ and 5′-CCTGGTGTCTGAAGTTCCCT-3′, which were designed
by theGenScript Real Time PrimerDesign Program.GAPDHexpressionwas used
to as normalization control and the primers were 5′-GCCAAAAGGGTCAT-
CATCTCT-3′ and 5′-GGTCATGAGTCCTTCCACGA-3′ [34]. Gene expression
was normalized to GADPH using the comparative Ct method (2−ΔΔCT) [35].2.6. Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was performed as described
previously [36] with some modifications. Briefly, cells were treated with 1%
formaldehyde for 15 min. Then cells were lysed in SDS buffer (1% SDS, 10 mM
EDTA, 50 mMTris, pH 8.1) containing protease inhibitor cocktail (Roche Applied
Science, IN, USA) and the lysatewas sonicated to shear theDNA to an average size
of 300–500 base pairs. The cell lysate was then diluted 9-fold in dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl, pH 8.1,
167 mMNaCl) and immunoprecipitated with antibodies against CREB, phospho-
CREB-Ser133, and control rabbit IgG at 4 °C overnight. No antibody reactions
served as a negative control. The immunoprecipitates were eluted in buffer (1%
SDS, 0.1 M NaHCO3) and then heated at 65 °C to reverse the crosslinking. After
RNase A and proteinase K digestion, the DNAwas purified by standard phenol/
chloroform extraction methods. The samples were analyzed by PCR with primer
sets specific for theRA-responsive region in the caspase-8 gene containing putative
CREB binding sites (5′-GACAGAGAAAGGGGAAATGG-3′; 5′-CCA-
GAAGCTTCTAGGGTATGATATG-3′) or HLA-G promoter region (5′-
TGCTCAAGTGCCTGACATTC-3′; 5′-GCTCCTTTTCCTCACCTCCT-3′) as a
positive control for the ChIP assay [37].
2.7. MTT assay
Cells grown in 24-well plates were incubated with 200 μl phenol red-free
RPMI 1640 containing 2% FBS and 0.5 mg/ml MTT for 3 h at 37 °C.
Isopropanol (200 μl) was then added to dissolve the MTT formazan crystals.
Absorbance was measured at 570 nm with background subtraction at 690 nm
and the cell viability was represented as a percentage of the control cells.
2.8. Reporter constructs and expression vectors
Different caspase-8 gene fragments were obtained by PCR amplification
using genomic DNA from NB cells as template and oligonucleotide primers
flanked by XhoI and HindIII restriction sites. The resulting fragments were then
cloned into the XhoI and HindIII sites of pGL3-basic vector (Promega, WI,
USA). The sequences of the primers are available upon request. Mutant versions
of the luciferase reporter plasmids were prepared by the QuikChange site-
directed mutagenesis kit (Stratagene, CA, USA) according to the manufacturer's
instructions.
Fig. 2. (A) Increased expression of caspase-8 was maintained in NB10 cells. NB10 cells were released into fresh medium after 2-day RA treatment, collected at
indicated times, lysed and subjected to immunoblot analysis. (B) Induction of caspase-8 mRNA in RA-released NB10 cells. NB10 cells were collected 4 days or
60 days after removal of RA and subjected to real-time PCR analysis. The caspase-8 mRNA expression was normalized to GADPH and the value for the relative
amount of caspase-8 in the untreated control sample was set as 1. The values represent the means±SD from at least 3 independent experiments.
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25 μg of the luciferase reporter plasmids and 2.5 μg of pRL-TK plasmid
(Promega, WI, USA) as an internal control for transfection efficacy. The
luciferase activity was determined by dual LUC reporter system (Promega, WI,
USA). Transfection efficiency was normalized by measuring Renilla luciferase
activity.
cDNAs encoding wild-type CREB (CREB-wt) and dominant-negative
CREB (CREB-m1) containing a mutation at the phosphorylation site (S133A),
kindly provided by Dr. D. Ginty [38], were subcloned into IRES2-EGFP vector
(Clontech, CA, USA).
The pSUPER.retro.neo+GFP retroviral vector (OligoEngine, WA, USA)
was used to generate a caspase-8 shRNA construct containing the 19-nucleotide
targeting sequence (5′-GGACTTCAGCAGAAATCTT-3′) for RNA interference
studies. The construct was then packaged and the resultant viruses were used
to infect the NB cells as described previously [5].Fig. 3. Long-term expression of caspase-8 is accompanied by decreases in
intragenicmethylation. (A)RAdid not change themethylation status of the caspase-
8 gene in most NB cells. NB8, NB12, NB19 and NB16 cell lines were treated with
RA for 4 days and subjected tomethylation-specific PCRof the caspase-8 gene. The
methylated primer set (upper, marked as “M”) produced a 321-bp product, and the
unmethylated primer set (lower, marked as “U”) produced a 322-bp product. Water
was used as a negative control of MS-PCR. (B) The caspase-8 gene is demethyl-
ated in RA-treated NB10 cells. NB10 cells were treated continuously with RA for
1–4 days or treated with RA for 2 days and released into fresh medium. The cells
were then collected at indicated time and subjected to MS-PCR.3. Results
3.1. RA inhibits cell proliferation of NB cells
To confirm that our NB cell lines exhibited growth inhibition
similar to that reported by others using different NB cell lines,
we monitored the effect of RA on two of our NB cell lines, NB8
and NB10. As expected, the number of BrdU positive cells
decreased significantly during RA treatment (Supplementary
Fig. 1A). We also analyzed cell cycle alterations in the RA-
treated cells by measuring the DNA content and by examining
expression of cell cycle regulatory proteins. The DNA contentFig. 4. The promoter region of the caspase-8 gene was not RA-responsive.
Schematic representations of full length of caspase-8 gene promoter region and
three fragments used for generating the deletion constructs are shown in the
upper panel. The numbers indicate the location of these fragments in the
caspase-8 gene relative to the transcriptional start site. The black lines represent
a putative RARE half-site. NB8 cells were transiently transfected with these
constructs and then treated with RA for 24 h. The transcriptional activity of these
constructs was determined by comparison of firefly luciferase activity with the
Renilla luciferase activity (lower panel). The relative luciferase activity in
vector-transfected control cells was set as 1.
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in sub-G1 apoptotic cells. The percentage of these apoptotic
cells varied between the different cell lines (Supplementary
Fig. 1B). In agreement with the DNA content data, the levels of
cyclin A, an essential protein for S-phase progression, and of
phosphorylated Rb were decreased by RA treatment (Supple-
mentary Fig. 1C). When cells were released from RA after a 2-
day treatment, cyclin A was re-expressed and Rb was re-
phosphorylated, indicating that cells were able to recover from
RA treatment and re-enter the cell cycle (Supplementary
Fig. 1C). These data support the conclusion that RA inhibits
proliferation of ourNB cell lines and are consistent with previously
reported results [22,39].Fig. 5. Identification of a RA-responsive region in the caspase-8 gene. (A) One of t
representations of the four fragments containing the putative RAREs used for generat
the putative RAREs. NB8 cells were transiently transfected with these constructs
transcriptional activity was measured 24 h after RA treatment (right panel). (B) R
Schematic representations of the constructs containing the full length RA-responsive
left panel. The relative luciferase activity of these constructs is shown in the ri
representations of the C8RARE-4 deletion fragments are shown in the left panel. Th
values represent the means±SD from at least 3 independent experiments.3.2. RA increases the expression of caspase-8 in NB cells
Due to the important role of caspase-8 in NB cells, we
examined the effect of RA on caspase-8 expression. Immuno-
blot analysis revealed that RA treatment increased caspase-8
expression in a time and dose dependent manner (Fig. 1A). To
determine whether similar effects could be observed in other
cell lines, we treated 10 additional NB cell lines with high
concentration of RA (100 μM). RA treatment increased the
expression of caspase-8 in 11/12 NB cell lines (Table 1).
Caspase-8 expression was even increased somewhat in NB16
cells (Fig. 1B), which have high initial levels of caspase-8 [5].
Consistent with the Western blot results, quantitative PCRhe four putative RAREs located within CASP8 was RA-responsive. Schematic
ing the different constructs are shown in the left panel. The black lines represent
and pRL-TK plasmid as an internal control for transfection efficiency. The
ARE sequences are not responsible for RA-mediated induction of caspase-8.
fragment (C8RARE-4) and the C8RARE-4 deletion fragments are shown in the
ght panel. (C) Location of the RA-responsive region in CASP8. Schematic
e relative luciferase activity of these constructs is shown in the right panel. The
Fig. 6. Mutation of the CREB binding site blocked RA-mediated induction of caspase-8 transcription. The sequence of the 105 bp RA-responsive region (C8frag04) is
shown in the upper right panel. The putative transcription factor binding sites for CREB and c-Myb are underlined. Constructs containing single mutations in CREB or
c-Myb binding sites and a double mutant were generated and used for transient transfection (right panel, lower). The relative luciferase activity was determined (left
panel). The values represent the means±SD from at least 3 independent experiments.
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abundance in NB8 and NB10 cells, while the increase was only
about 2-fold in NB16 cells (Fig. 1C). These data suggest that
RA regulated caspase-8 transcription or mRNA stability.Fig. 7. RA induced CREB phosphorylation and increased CREB DNA binding activ
been treated continuously with RA for 1 to 4 days or treated with RA for 2 days and r
immunoblot analysis with antibodies against CREB or phospho-CREB (Ser-133). (
performed with nuclear extracts (NEs) from untreated NB10 (lanes 2–7) or RA-treate
CREB binding site in CASP8 (5′-AAGAACGAAATGACGCAATCTCCAGAT-3′).
Free probe was also loaded as a negative control (lane 1). Competition assays were p
an unlabeled mutant oligonucleotide probe (5′-AAGAACGAAATGTGGCAATCTC
BSA (lanes 5 and11), serum (lanes 6 and 12), or an anti-phospho-CREB antibody
supershifted bands. (C) RA enhanced in vivo CREB binding. NB10 cells were treate
formaldehyde and sheared chromatin was immunoprecipitated with rabbit IgG, C
amplification was also performed using input DNA from the lysed cells prior to imm
treatment. (D) RA treatment causes phosphorylation of the majority of cellular CRE
described above. ChIP analysis was performed on NB10 cell lysates depleted with
treatment; “+”: with RA treatment.We also examined the effects of other forms of retinoids on
caspase-8 expression. All the four forms of retinoids up-
regulated caspase-8 expression in NB cells (Fig. 1D). RA and
13-cis RA were more effective than 9-cis RA in inducingity. (A) RA increased the phosphorylation of CREB at Ser133. Cells which had
eleased into fresh medium were collected at the indicated times and subjected to
B) CREB binding activity was enhanced by RA in vitro. EMSA analysis was
d cells (lanes 8-13) and a 32P-labeled oligonucleotide encompassing the putative
The reactions were then subjected to gel electrophoresis and autoradiography.
erformed using a 100-fold excess of unlabeled oligonucleotide (lanes 3 and 9) or
CAGAT-3′) (lanes 4 and 10). Supershift assays were performed by addition of
(lanes 7 and13). The arrow indicates retarded bands and the asterisk indicates
d with RA for 24 h and subjected to ChIP analysis. The cells were fixed in 1%
REB, pCREB (Ser133) antibodies along with a no antibody control. PCR
unoprecipitation as a positive control. “−”: without RA treatment; “+”: with RA
B. NB10 cells were treated with RA for 24 h and subjected to ChIP analysis as
control, pCREB, CREB or both (“pCreb/Creb”) antibodies. “−”: without RA
Fig. 8. Overexpression of a dominant-negative form of CREB repressed RA
induced caspase-8 up-regulation. NB8 cells were transfected with control vector
(IRES2-EGFP), CREB-wt (wild-type), or CREB-m1 (dominant-negative)
constructs. Two days later, the GFP-positive cells were isolated and exposed to
RA for 3 days prior to immunoblot analysis with the indicated antibodies. “−”:
without RA treatment; “+”: with RA treatment.
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Importantly, retinoids treatment increased caspase-8 protein
levels in several medulloblastoma (BT-3, BT-4) and small cell
lung carcinoma (NCI-H82, NCI-H889) cell lines which lack
caspase-8 expression, indicating that the ability of these
compounds to induce caspase-8 was not limited to neuroblas-
toma (Fig. 1E).
To investigate the duration of RA-mediated effects on
caspase-8 expression, twelve NB cell lines were treated with
RA for 2 days. RA was then removed and the cells were
monitored to determine how long caspase-8 levels remained
elevated. Although the maintenance time of caspase-8 up-
regulation was cell line dependent, in all cases caspase-8
remained elevated for at least 2 days (Table 1). To our surprise,
caspase-8 expression was retained at the same level for 38 days
in NB10 cells. Furthermore, the level of caspase-8 mRNA and
protein increased further on ~ day 42. This increased level of
caspase-8 was maintained for N120 days in NB10 cells (Fig. 2).
Further studies to address the processes involved in this long-
term change in caspase-8 expression are ongoing.
Since previous studies established a correlation between
reduced caspase-8 expression and methylation of an intragenic
region of the caspase-8 gene [5,40,41], we used methylation-
specific PCR to determine the methylation status of caspase-8
after RA treatment. Following RA treatment the caspase-8 gene
remained methylated in NB8, NB12 and NB19 cells and
unmethylated in NB16 cells (Fig. 3A). Surprisingly however, in
NB10 cells RA treatment led to demethylation of the caspase-8
gene (Fig. 3B).
3.3. Identification of a RA-responsive region in the caspase-8 gene
To determine the mechanism of caspase-8 up-regulation, we
measured caspase-8 promoter activity after RA treatment by
transfecting luciferase reporter plasmids containing either the
entire functional promoter region [42–44] or smaller promoter
fragments into NB8 cells (Fig. 4, upper panel). The transcrip-
tional activity of these constructs was measured by comparison
of the firefly luciferase activity to the control Renilla luciferase
activity in the presence and absence of RA. The full length
caspase-8 promoter (pC8-1108, −1108/+81) and the two longer
truncation constructs (pC8-609: −609/+81; pC8-197: −197/
+81) had similar transcriptional activity, while the smallest
fragment (pC8-108: −108/+81) exhibited lower levels of
expression, implying that this fragment contains the caspase-8
basal promoter. Somewhat surprisingly, no changes in tran-
scriptional activity of any of these constructs were observed
after RA treatment despite the presence of the RARE half-site
(AGGTCA) located at −694 (Fig. 4). These results suggest that
other regions in the caspase-8 gene mediate RA-responsiveness.
Computer analysis indicated that there are four potential
RAREs located within the caspase-8 gene (−7733, +23778,
+34847 and +46249), all of which have the same DR2 sequence
(AGGTCAGGAGTTCA). To determine whether any of these
sites were RA-responsive, caspase-8 genomic regions containing
the four RAREswere cloned into the pGL3-basic vector (Fig. 5A,
left panel). The fragments containing sites 1 and 3, C8RARE-1(−8494/−6895) and C8RARE-3 (+34068/+35667), had no
transcriptional activity even in the presence of RA. The fragment
containing the second RARE (C8RARE-2, +22989/+24588)
activated transcription in the absence of RA, although no increase
in the transcriptional activity was observed upon the addition of
RA (Fig. 5A, right panel). In contrast, RA induced the tran-
scriptional activity of the construct containing the C8RARE-4
fragment (+45441/+46953) approximately 6-fold, indicating that
this fragment was RA-responsive (Fig. 5A).
To further localize the sequences that were required for RA-
responsiveness, we performed a detailed analysis of this region
by generating three deleted constructs containing progressively
smaller sequence regions flanking the RARE-4 sequence
(Fig. 5B, left panel). Surprisingly, none of the smaller constructs
were induced by RA despite the presence of the RARE
sequence in all three fragments, suggesting that this sequence
was not responsible for RA-responsiveness (Fig. 5B). There-
fore, we generated additional constructs containing other
portions of the C8RARE-4 fragment. Using these constructs
we identified a 105 bp fragment (+46849/+46953, termed a
C8frag04) that was induced by RA (Fig. 5C). This fragment
contained two potential transcription factor binding sites: a
CREB site and a c-Myb site.
To determinewhether either of these transcription factor binding
sites contributed to the RA induction, we generated constructs with
point mutations in these sites. Mutation of the CREB binding site
completely blocked RA induction, while mutation of the c-Myb
binding site had no effect onRA-responsive transcriptional activity.
The double mutant construct blocked RA induction to the same
extent as the CREB single mutant (Fig. 6).
3.4. RA induces CREB phosphorylation and increases DNA
binding activity of CREB
CREB (cAMP-response element-binding protein) is a
nuclear transcription factor which is activated by phosphoryla-
tion at serine 133 [45]. To investigate the role of CREB in
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CREB mRNA and protein expression. Real-time PCR results
showed no significant change in CREB mRNA levels after RA
treatment in NB8, NB10 or NB16 cell lines (data not shown).
Similarly, RA treatment had no effect on expression of the
CREB protein (Fig. 7A). However, RA increased the levels of
Ser133-phosphorylated CREB, which is the active form of
CREB in the NB cell lines (Fig. 7A).
To determine whether RA-activated CREB binds to the RA-
responsive CREB site we identified within caspase-8, weFig. 9. RA sensitizes NB cells to TNFα- or drug-induced apoptosis. (A) RA sensitize
into fresh medium. Ten days later, the cells were treated with TNFα (100 ng/ml) plus c
(20 μM). The cells were also treated with CHX or zVAD alone as controls. Cell viabi
NB10 cells to doxorubicin (Dox). The RA-released NB10 cells prepared as described
student t-test indicates that responses of the control and RA-treated cells are statisti
negative form of CREB repressed RA-mediated sensitization to TNFα or Dox. NB
negative) constructs, sorted and treated with RA for 3 days. NB8 cells were release
viability was measured using an MTT assay. (D) RNA interference of caspase-8 in
retrovirus supernatants containing vector (pSuper.retro.neo+GFP) or caspase-8 shRN
expressed GFP at this time. The cells were then treated with TNFα or Dox for 24 h an
independent experiments. (E) Caspase-8 was activated during TNFα- or Dox-induce
with TNFα (T) or Dox (D) for 24 h and subjected to immunoblot analysis using thecarried out gel shift (EMSA) analysis using a 32P-labeled
oligonucleotide containing the putative CREB binding site and
nuclear extracts isolated from control NB10 cells and NB10
cells which were treated with RA for 24 h. Specific gel shift
bands indicative of interaction between proteins and the probe
were observed with both control and RA-treated nuclear
extracts, however, the intensity of these bands was dramatically
increased when nuclear extracts from RA-treated cells were
used for the assay (Fig. 7B, lanes 2 and 8). This binding was
specific because the band shift was eliminated by competitions NB10 cells to TNFα. NB10 cells were treated with RA for 2 days and released
ycloheximide (CHX, 1 μg/ml) with and without the caspase inhibitor zVAD-fmk
lity was measured using an MTT assay after a 24-h treatment. (B) RA sensitized
above were treated with Dox (1 μg/ml) for 24 h and used for a MTT assay. The
cally significant different ( p-valuesb0.05). (C) Overexpression of a dominant-
8 cells were transfected with vector (IRES2-EGFP), or CREB-m1 (dominant-
d from RA and treated with TNFα and Dox for 24-h as described above. Cell
hibited RA-mediated sensitization. RA-released NB10 cells were infected with
A (C8-shRNA) for 2 days. Microscope analysis demonstrated that N80% of cells
d used for a MTT assay. The values in (A–D) are means±SD from at least three
d apoptosis. RA-released NB10 cells prepared as described above were treated
indicated antibodies.
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lanes 3 and 9), but not by the addition of unlabeled mutant
probe, BSA, or serum (Fig. 7B, lanes 4–6 and 10–12). The
specificity of the interactions was further verified by the
observation that the bands were shifted to a higher molecular
mass upon addition of pCREB (Ser133) antibodies (Fig. 7B,
lanes 7 and 13), confirming that the bands were due to the
binding of CREB to the oligonucleotides.
To further investigate the effects of RA on DNA binding
activity of CREB in vivo, we performed chromatin immuno-
precipitation analysis (ChIP). Sheared cross-linked chromatin
fragments were immunoprecipitated with control rabbit IgG,
anti-CREB antibodies, and an antibody recognizing the Ser133-
phosphorylated form of CREB antibodies along with a no
antibody control. We also amplified the promoter region of
HLA-G, which has been shown to be bound by CREB using the
ChIP assay, as a positive control [37]. ChIP analysis demon-
strated in vivo binding of CREB to the RA-responsive region in
the caspase-8 gene (Fig. 7C). Consistent with the EMSA data,
more PCR products were obtained in ChIP assays from RA-
treated cells (Fig. 7C), suggesting RA induced increased DNA
binding of CREB to the caspase-8 gene in vivo. Furthermore, no
PCR product was obtained from CREB antibody immunopre-
cipitates after depleting the extract of phospho-Ser133-CREB,
indicating that most of the CREB protein that binds to caspase-8
in RA-treated cells is phosphorylated (Fig. 7D).
3.5. Overexpression of a dominant-negative form of CREB
represses caspase-8 induction by RA
To determine whether CREB activation is necessary for
caspase-8 up-regulation, we overexpressed wild-type (CREB-
wt) and a dominant-negative mutant CREB (CREB-m1,
S133A) which prevents phosphorylation and the binding of
CREB to co-activator proteins [38]. For these studies, NB8 cells
were transfected with the CREB constructs for 2 days, and the
sorted GFP-positive cells were exposed to RA for another
3 days. Immunoblot analysis revealed that caspase-8 expression
was much lower in RA-treated cells transfected with CREB-m1
compared to cells transfected with the vector or a CREB-wt
construct (Fig. 8), suggesting that activity of CREB is necessary
for the induction of caspase-8 by RA.
3.6. RA-mediated increases in caspase-8 sensitize NB cells to
TNFα- or drug-induced apoptosis
To determine whether the up-regulation of caspase-8 has
functional significance, we examined the effect of RA treatment
and caspase-8 induction on cell death. For these studies, NB10
cells were treated for 2 days with RA and then released into
fresh media. Ten days after release, the cells were treated with
TNFα plus cycloheximide in the presence or absence of zVAD-
fmk. RA-released cells were more sensitive to TNFα, while the
addition of the caspase inhibitor zVAD repressed cell death
(Fig. 9A). Similar results were obtained with more specific
caspase-8 inhibitor z-IETD-fmk (data not shown), supporting
the conclusion that caspase-8 was involved in this process. Wenext checked the cell response to another apoptosis-inducing
reagent, doxorubicin (Dox). Dox has been reported to trigger
apoptosis primarily through the death receptor pathway in
leukemic T cells and neuroblastoma cells [31,46,47], although
this drug induces cell death via the mitochondrial pathway in
other cell types [48,49]. RA treatment increased Dox sensitivity
in NB10. This increase in apoptosis was inhibited by zVAD
(Fig. 9B). Similar responses were observed in RA-released NB8
cells (data not shown). Importantly, expression of a dominant-
negative CREB mutant protein caused the transfected NB8 cells
to become resistant to TNFα and Dox following RA treatment
and release (Fig. 9C).
To further investigate the contribution of caspase-8 to RA-
mediated sensitization, we used RNA interference to decrease
caspase-8 expression. As shown in Fig. 9D, the RA-released
NB10 cells which were expressing caspase-8 shRNA (C8-
shRNA) were resistant to TNFα and Dox. We also explored the
activation of caspase-8 by monitoring caspase-8 cleavage and
activation of downstream caspases in TNFα and Dox treated
cells. Caspase-8 was cleaved to an active form after TNFα and
Dox treatment in vector infected cells, but not in C8-shRNA
expressing cells (Fig. 9E). In addition, the caspase-8 substrate
caspase-3 was cleaved only in vector infected cells, as was the
caspase-3 substrate PARP (Fig. 9E). Furthermore, we found that
expression of the upstream proteins Fas and FADD were
increased in both vector and C8-ShRNA infected cells. TNF
receptor 1 (TNFR1) was up-regulated only in TNFα treated
cells and TRAIL receptor 2 (DR5) was induced only in Dox
treated cells. These data support the conclusion that caspase-8
was activated during TNFα- and Dox-induced apoptosis after
RA removal.
4. Discussion
Caspase-8 is deleted or silenced in most NB cell lines and
many patient tumor samples [5–7]. Loss of caspase-8 expres-
sion has also been observed in other tumors such as
medulloblastoma, small cell lung carcinoma and colorectal
carcinomas [14–17]. In medulloblastoma, the loss of caspase-8
correlates with unfavorable survival outcome [17]. Addition-
ally, animal models and cell culture studies have demonstrated
that the loss of caspase-8 enhances the metastatic potential of
NB cells [8–10]. Caspase-8-deficient NB cells are resistant to
death receptor signals and some chemotherapeutic drugs
[5,31,41,50]. These defects can be corrected by re-expression
of caspase-8 via demethylating agents, caspase-8 expressing
retroviral vectors and IFN-γ treatment [5,31,41,50–53]. Re-
expression of caspase-8 by IFN-γ or demethylating agents
sensitizes cells to radio- and chemotherapy in medulloblastoma
cells [53,54]. In a search of other agents that are more easily
tolerated than those described above, we investigated the effects
of all-trans retinoic acid (RA) treatment on caspase-8 expres-
sion and cellular proliferation in NB cells. Here we show that
activation of caspase-8 by retinoic acid sensitizes neuroblas-
toma cells to TNFα- or drug-induced apoptosis.
Our results indicate that RA increases the expression of
caspase-8 in most NB cell lines (11/12) to varying extents
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Table 1). Further, we show that RA up-regulates the caspase-8
gene at the RNA level (Fig. 1C). Moreover, all the forms of
retinoids (RA, 13-cis RA, 9-cis RA and 4HPR) increase
caspase-8 expression not only in NB cell lines, but also in
medulloblastoma and small cell lung carcinoma cell lines
(Fig. 1D and E). Previous work has identified a region within
the caspase-8 gene which is methylated. Methylation of this
region has been correlated with decreased caspase-8 protein in
some studies [5,40,41], but not in others [42,55]. Several studies
have shown that demethylation of this region is not required for
re-expression of caspase-8 in response to IFN-γ [31,50,56].
Here we show by methylation-specific PCR that RA treatment
does not alter the methylation status of this region in the major-
ity of NB cell lines. Strikingly however, a single 2-day treat-
ment of one cell line, NB10, with RA resulted in continued
expression of caspase-8 for more than 120 days (Fig. 2 and
Table 1). Furthermore, the sustained expression of caspase-8
correlated with the appearance of unmethylated caspase-8 inter-
genic DNA sequences (Fig. 3). While this correlation is note-
worthy, many more studies are needed to determine whether this
change in methylation is responsible for the sustained increase
in caspase-8 expression we observed in this cell line.
The effects of RA on gene transcription are mainly mediated
through the binding of retinoic acid receptors (RARs) and retinoid
X receptors (RXRs) to RA response elements (RAREs) in the
target gene [25,26]. Here we show that the transcriptional activity
of the caspase-8 promoter (−1108/+81) was not induced by RA,
despite the presence of a RAREhalf-site (Fig. 4). These data are in
contrast with another study which showed that the transcriptional
activity of the caspase-8 promoter (−1161/+16) was induced by
4HPR, an RA analog [43]. Although the reasons for this
discrepancy are not clear, it should be noted that RA and 4HPR
have been reported to act by different pathways [20,57,58].
Since we found that the caspase-8 promoter is not RA-
responsive, we also examined the four putative RAREs within the
caspase-8 gene. None of these sequences were RA-inducible,
suggesting that RA up-regulates caspase-8 independent of
RAREs (Fig. 5). Several recent studies have shown that RA can
also stimulate other cellular signaling pathways, which are
independent of receptor binding toRAREs [28–30]. For example,
RA can regulate PKCα activity by competing with phosphati-
dylserine for a binding site in the C2-domain of PKCα [29,30]. In
addition, other studies have demonstrated that RA-mediated
activation of CREB can increase expression of c-fos, which does
not contain RAREs in its promoter [28]. Here we identify a RA-
responsive region in intron 8 of the caspase-8 gene and localize
the responsive element to a region containing a CREB binding
site (Fig. 6). While we were somewhat surprised by this finding,
intronic sequences have been found to be involved in transcrip-
tional regulation of other genes. Intronic enhancement of gene
expression was first identified in human alpha-1 collagen gene
[59], and was further found in other genes including the CD21,
ALAS2, delta1-crystallin, CRP1 and Opalin genes [60–64].
Intronic sequences can also function as gene silencer in some
genes such as CD4 and OTR [65,66]. Intronic control of gene
transcription usually involves the binding of transcription factorsto the DNA sequence [61–64]. Importantly, previous studies have
demonstrated that active CREB binding to intronic region of the
CRP1 and Opalin genes results in increased expression of these
genes [63,64]. Our gel shift and chromatin IP assays reveal an
increase in CREB binding to an intronic region of the caspase-8
gene in RA-treated NB cells (Fig. 7B and C). This data in
conjunction with data from studies using a dominant-negative
CREB mutant support the conclusion that CREB binding to this
responsive region is required for RA induced caspase-8
expression. This result is also consistent with reports indicating
that DNA binding activity of CREB is increased by RA or other
stimuli [67,68].
CREB is a nuclear transcription factor which is very important
in controlling cell growth, survival, proliferation and cell fate
decisions [45]. CREB forms dimers with the co-activator CREB
binding protein (CBP) which bind to the cAMP-response element
(CRE, TGACGTCA) or the half-site of CRE (TGACG/CGTCA)
[45,69]. In addition to CRE-binding, activation of CREB requires
phosphorylation at serine 133. Numerous kinases including
pp90rsk, PKA, PKC, AKT, MSK-1, MAPKAP-2, and calcium–
calmodulin kinases II/IV phosphorylate CREB in response to
various stimuli [45,69,70]. Importantly, phosphorylation of
CREB is required for the interaction of CREB with the co-
activator protein CBP.
Our data demonstrates that RA increases the amount of CREB
bound to the CREB binding site in intron 8 ofCASP8 in NB cells
(Fig. 7B and C). It is interesting that most of the CREB bound
oligonucleotide in the retarded band is supershifted by the anti-
phospho-CREB antibody (Fig. 7B). This data and similar data
from another study using RA in human tracheobronchial
epithelial cells [68] support the conclusion that most cellular
CREB protein is phosphorylated following RA treatment. The
chromatin IP data demonstrating that cellular lysates immunode-
pleted of phospho-CREB no longer contain any chromatin-bound
CREB further support this conclusion (Fig. 7D). Finally,
overexpression of a dominant-negative form of CREB repressed
caspase-8 expression during RA treatment, further confirming
that CREB function is necessary for induction of caspase-8 byRA
(Fig. 8).
Although the mechanism of activation of CREB by RA is not
well understood, several recent studies demonstrated that RA
activates CREB in an ATM-dependent or a PKCα-dependent
manner [70,71]. Further, induction of CREB phosphorylation is
very rapid and seems to be independent of the binding of RA
receptors to RAREs [28]. Two recently published papers
strongly support this conclusion, since depletion of RARs and
RXRα via siRNA did not block the activation of CREB by RA
[68,70]. It remains to be determined whether CREB phosphor-
ylation is induced by similar mechanisms in neuroblastoma
cells. Importantly, these data also suggest multiple stimuli could
induce and/or regulate caspase-8 expression via altering CREB
phosphorylation. Further studies are clearly needed to address
this possibility.
In addition to inducing CREB phosphorylation, RA inhibits
cellular proliferation in NB cells as judged by analysis of DNA
content, BrdU incorporation, decreased expression of cyclin A
and dephosphorylation of Rb (Supplementary Fig. 1). RA
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length (data not shown), indicating that RA induces at least partial
differentiation. However, when RA was removed the cells were
capable of rapidly re-entering the cell cycle based on cyclin A re-
expression and Rb phosphorylation (Supplementary Fig. 1C).
These data indicate both that RA is cytostatic and that NB cells are
likely to be resistant to many chemotherapeutic agents during RA
treatment since cellular proliferation is required for the action of
most chemotherapeutic agents. This suggests that agents such as
TRAIL would be effective during RA treatment while most
chemotherapeutics would not. However, since caspase-8 expres-
sion remains elevated in most NB cells for at least 2 days after the
removal of RA, and in the case of NB8 and NB10 for 15 and
N120 days, respectively (Fig. 2 and Table 1), and cellular
proliferation resumes during this time period, RA-released cells
should be more sensitive to chemotherapeutic agents. Indeed, our
data indicate that RA-released cells displayed increased apoptosis
in response to doxorubicin and TNFα following RA release
(Fig. 9A and B). This increased responsiveness is at least partially
dependent on caspase-8 expression and activation, because not
only is caspase-8 activated by cleavage, but also the caspase
inhibitors zVAD and z-IETD repressed cell death (Fig. 9 and data
not shown). Furthermore, specific inhibition of caspase-8 using
RNA interference repressed cell death induced by TNFα and Dox
(Fig. 9D). Thus, RA is a potential therapeutic agent for increasing
the response of NB cells to both receptor-mediated death signals,
such as TRAIL, and to standard cytotoxic reagents such as
doxorubicin. Importantly, the data also indicate that further
preclinical studies combining RA with other agents are clearly
warranted.
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